DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Attention Pharmacists: Florida HB423
March 13, 2017

ARNP’s and PA’s, if you have questions regarding the Florida House Bill 423 and how it affects you, this free, informative webinar is for you! Continue reading


Imagineering the Future of Pharmacy Regulation
March 2, 2017

The boards of pharmacy will elect officers and members of the NABP Executive Committee, review and vote on NABP policies, and guide the direction of the Association Continue reading